文献速递妇科

术前近距离放疗后行根治性子宫切除术对IB2期(FIGO 2018)宫颈癌的影响:SENTICOL I-II试验分析

Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials.
PubMed 文献 · Gynecol Oncol · 2023-02-07

基于SENTICOL I与II两项法国前瞻性多中心试验的回顾性分析,纳入104例肿瘤2–4 cm(FIGO 2018 IB2)宫颈癌患者,比较术前近距离放疗后根治性子宫切除术与直接手术的结局。术前近距离放疗组无残留病变比例更高、按Sedlis标准低危比例更高、辅助治疗更少,但≥3级术后并发症更多,5年无病生存率更高。

要点

  • 术前近距离放疗组无残留病变71.4%,直接手术组25.5%(p < 0.0001)。
  • 术前近距离放疗组≥3级术后并发症24.5%,直接手术组9.1%(p = 0.03)。
  • 5年无病生存率术前近距离放疗组93.6%,直接手术组74.4%(p = 0.04)。

核心结论

  • 术前近距离放疗虽与更严重的术后并发症显著相关,但手术标本病理特征更好,并使IB2期宫颈癌的5年无病生存率更高。

研究设计与样本

  • SENTICOL I与SENTICOL II为2005年至2012年开展的两项法国前瞻性多中心试验,评估早期宫颈癌前哨淋巴结活检。
  • 对SENTICOL I与SENTICOL II队列进行回顾性分析,比较IB2期宫颈肿瘤患者接受术前近距离放疗或直接手术的结局。
  • 共纳入104例患者:55例接受直接根治性子宫切除术,49例接受术前近距离放疗后根治性子宫切除术。
  • 术前近距离放疗(低剂量率或脉冲剂量率,剂量60Gy)可在根治性子宫切除术前6至8周进行,由各中心自行决定。

主要发现

  • 术前近距离放疗组无残留病变比例71.4%,直接手术组25.5%(p < 0.0001)。
  • 按Sedlis标准定义为低危者术前近距离放疗组83.3%,直接手术组51.2%(p < 0.0001)。
  • 需要辅助治疗者术前近距离放疗组14.3%,直接手术组54.5%(p < 0.0001)。
  • ≥3级术后并发症术前近距离放疗组24.5%,直接手术组9.1%(p = 0.03)。
  • 5年无病生存率术前近距离放疗组93.6%,直接手术组74.4%(p = 0.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The goal of this study was to compare the outcomes of preoperative brachytherapy followed by radical surgery versus radical surgery alone in cervical cancer with tumor between 2 and 4 cm (FIGO 2018 IB2). MATERIAL AND METHODS: SENTICOL I and SENTICOL II were two French prospective multicentric trials evaluating sentinel node biopsy in early-stage cervical cancer between 2005 and 2012. Preoperative brachytherapy (low-dose rate or pulse-dose rate at the dose of 60Gy) could be performed 6 to 8 weeks prior to the radical hysterectomy, at the discretion of each center. SENTICOL I and SENTICOL II cohorts were retrospectively analysed to compare the outcomes of preoperative brachytherapy or upfront surgery in patients with IB2 cervical tumor. RESULTS: A total of 104 patients were included: 55 underwent upfront radical hysterectomy and 49 underwent preoperative brachytherapy followed by radical hysterectomy. Patients with preoperative brachytherapy were more likely to have no residual disease (71.4% vs. 25.5%, p < 0.0001) and to be defined as low risk according to Sedlis criteria (83.3% vs. 51.2%, p < 0.0001). Adjuvant treatments were required less frequently in case of preoperative brachytherapy (14.3% vs. 54.5%, p < 0.0001). Patients with preoperative brachytherapy experienced more postoperative complications grade ≥ 3 (24.5% vs. 9.1%, p = 0.03). Patients with preoperative brachytherapy had better 5-year disease-free survival compared to patients who underwent surgery alone, 93.6% and 74.4% respectively (p = 0.04). CONCLUSION: Although preoperative brachytherapy was significantly associated with more severe postoperative complications, better pathologic features were obtained on surgical specimens and led to a better 5-year disease-free survival in IB2 cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kissel M, Balaya V, Guani B, et al. Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials. Gynecol Oncol. 2023. PMID: 36758421. doi:10.1016/j.ygyno.2023.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。